Previous 10 | Next 10 |
2023-08-10 20:43:04 ET Oncternal Therapeutics, Inc. (ONCT) Q2 2023 Earnings Conference Call August 10, 2023 05:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Carl By...
2023-08-10 16:02:52 ET Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q2 GAAP EPS of -$0.15 beats by $0.02 . Revenue of $0.11M (-42.1% Y/Y) misses by $0.06M . Cash runway extended into 2025, with $45.5 million in cash, cash equivalents and short-term ...
Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling inhibitors Dosed the first patient in our Phase 1/2 study for ONCT-808, our ROR1...
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial markets c...
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), ...
SAN DIEGO, June 06, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study ...
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that Dr. James Breitmeyer, Oncternal’s President and Chief Executive Officer will pres...
2023-05-04 22:53:04 ET Oncternal Therapeutics, Inc. (ONCT) Q1 2023 Results Conference Call May 04, 2023 5:00 PM ET Company Participants Salim Yazji - CMO James Breitmeyer - President, CEO Richard Vincent - CFO Conference Call Participants Hartaj Singh...
2023-05-04 16:52:52 ET Oncternal Therapeutics press release ( NASDAQ: ONCT ): Q1 GAAP EPS of -$0.20 in-line. Revenue of $0.2M (-71.4% Y/Y) beats by $0.06M . For further details see: Oncternal Therapeutics GAAP EPS of -$0.20 in-line, revenue of $0.2M beats by ...
Phase 1/2 study initiated for ONCT-808, our autologous CAR-T targeting ROR1-expressing hematologic malignancies, with initial clinical data expected in late 2023 Final IND-enabling studies completed for ONCT-534, our novel dual-action androgen receptor inhibitor (DAARI), with expected IND...
News, Short Squeeze, Breakout and More Instantly...
Oncternal Therapeutics Inc. Company Name:
ONCT Stock Symbol:
NYSE Market:
Oncternal Therapeutics Inc. Website:
2024-06-26 15:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that enrollment has been completed and dosing initiated for the fifth dose cohort of its Phas...
Fourth dosing cohort at 300 mg per day is fully enrolled for the Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitors; initial data readout expected in the ...